Salix Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Salix Pharmaceuticals Ltd.
From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.
During Bausch Health’s first quarter earnings call, CEO Papa said he’ll lead Bausch + Lomb following the corporate split. Overall the company reported flat revenues, but said its pandemic rebound is ongoing.
Gilead outlines efforts to expand availability of remdesivir in India while offers for supplies from Russia, Uzbekistan are also on the table. Zydus Cadila has received accelerated approval in India for pegylated interferon alpha-2b in moderate COVID-19 infection in adults.
As India sees a consistent rise in daily cases and deaths due to COVID-19, the off-patent industry is stepping up to make drugs affordable and available. Zydus Cadila is seeking approval for virafin, while Natco has applied for molnupiravir approval. Vaccine production and availability has also come under focus.
- Other Names / Subsidiaries
- InKine Pharmaceutical
- Oceana Therapeutics, LLC
- Q-Med Scandinavia, Inc.
- Santarus, Inc.